More than 90% of Indian patients with diffuse large B-cell lymphoma (DLBCL) treated from 2014 to 2015 had access to rituximab due to the biosimilar’s availability.
In patients with diffuse large B-cell lymphoma (DLBCL), rituximab is typically administered with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy for 4 to 6 cycles in early stages and 6 to 8 cycles in advanced stages. While the branded rituximab has been available as MabThera in India since 2002, it was too expensive for widespread use. In 2007, a biosimilar (marketed as Reditux) came to market in India, but there have been few data published on the efficacy of this biosimilar in treating Indian patients with DLBCL.
A recent study, published in the Indian Journal of Cancer, reports outcomes of young patients (n = 444), aged 15 to 60 years, treated between 2000 and 2013 in a tertiary cancer center that serves primarily lower-socioeconomic status patients who received rituximab therapy in conjunction with CHOP.
All patients received CHOP, with rituximab (n = 119) or without rituximab (n = 325). Prior to the availability of the biosimilar, only patients who could afford reference rituximab via private insurance or out-of-pocket had access to the drug. After biosimilar market entry, most patients receiving rituximab were given the biosimilar. From the first year of the study to the last year, the proportion of patients receiving rituximab with CHOP increased from no patients to nearly three-quarters of all patients.
In those who received rituximab with their chemotherapy versus those who received CHOP alone, complete response rate was improved (83.8% versus 73.7%; P = .024). Among patients who received rituximab, 5-year overall survival was 81%, versus 64% for those who received CHOP alone (P = .040).
According to the authors, these findings are key to helping to understand the efficacy of the biosimilar; in India, biosimilars are sometimes approved for use without a large phase 3 efficacy trial to compare a biosimilar to its reference. In the case of this rituximab biosimilar, approval was based on a single-arm study in patients with DLBCL.
“Although these results are not a substitute for randomized phase 3 trials, these can increase confidence among physicians using the biosimilar molecule when it is not possible (due to economic considerations) to use the innovator product,” say the authors, noting that more than 90% of patients with DLBCL treated from 2014 to 2015 had access to rituximab due to the biosimilar’s availability.
Reference
Ganesan P, Sagar TG, Kannan K, et al. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation. Indian J Cancer. 2017;54:430-5. doi: 10.4103/ijc.IJC_241_17.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
January 16th 2025Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.